Sanofi, Google team up on diabetes; Lilly, Boehringer nab FDA approval for SGLT2 combo med; Allergan wraps Naurex deal;

@FiercePharma: ICYMI: Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse. Article | Follow @FiercePharma

@EricPFierce: Majority of Mylan shareholders approve buyout of Perrigo, despite adamant opposition by its management. Press release | Follow @EricPFierce

@CarlyHFierce: 'No signal' of heart failure risk with Merck's Januvia, analysis confirms. Article | Follow @CarlyHFierce

> Sanofi ($SNY) inked a deal with Google's ($GOOG) newly launched life sciences division to work together on new treatment approaches, including digital-plus-drug approaches. Report

> Eli Lilly & Co. ($LLY) and Boehringer Ingelheim's new diabetes combo med Synjardy--which combines the active ingredient in the SGLT2 drug Jardiance with metformin--won U.S. approval, becoming the third empagliflozin product blessed by the FDA. Release

> Allergan ($AGN) wrapped up its $560-million-plus deal for Naurex and its two antidepressants, which recently posted promising mid-stage data. Release

> Novartis' ($NVS) eye care division Alcon Laboratories, Johnson & Johnson ($JNJ) and Bausch & Lomb struggled to defend their pricing policies in a federal appeals court Thursday, with the judges repeatedly challenging the companies' arguments. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: $GOOG and $SNY are teaming up for #diabetes monitoring. More from the WSJ | Follow @EmilyWFierce

> Google pairs with Sanofi for diabetes monitoring collaboration. Story

> Precedent from Amarin's off-label promotion victory covers devices, too, especially those marketing a surrogate endpoint. Editor's Corner

> Philips debuts two new cardio products to European market at London conference. Article

Biotech News

@FierceBiotech: Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential. Article | Follow @FierceBiotech

@JohnCFierce: Amicus bags PhIII rare disease drug in $847M Scioderm buyout. News | Follow @JohnCFierce

@DamianFierce: Missed the FDA biosimilar-naming thing because vacation, but I'm a big fan of the phrase "suffix devoid of meaning." More | Follow @DamianFierce

> Intercept wins priority review for OCA. Item

> Sanofi buys into Google's biotech future, pairing up in diabetes. Story

> Bayer takes its heart-failure drug into Phase III after a mid-stage success. Report

> Step 3: After an immunotherapy makeover, CytomX files $100M IPO. More

Animal Health News

> Denver cannabis seller teams with vet to launch pet wellness line. Item

> Cornell U spotlights veterinary profession on Nat Geo reality TV show. News

> Patterson shares fall on missed sales and earnings targets. More

> Young entrepreneur shows off veterinary product at White House Demo Day. Story

> Academic docs and biotechs partner with veterinarians to find cancer cures. Article

Biotech IT News

> Ginkgo Bioworks allies with Ajinomoto to expand into amino acid production. Item

> Venter's HLI nabs Millennium Health COO to oversee global expansion. Report

> Mytrus makes electronic informed consent breakthrough in U.K. Story

> How openFDA's 'crazy collision' of Silicon Valley and federal culture is reshaping the regulator. More

> UCL taps Elsevier resource to advance drug repurposing research. Article

Pharma Marketing News

> The 'Kardashian Effect' on pharma begs the question: Does social media influence drug requests? Story

> The need-to-know from ESC (so far): Merck, BMS, Pfizer and Sanofi. More

> Repatha vs. Praluent matchup has Amgen, Sanofi zeroing in on key details. Article

> Dutch pension fund dumps Mylan on worries about death penalty drug. Item

> Want to improve drug adherence, pharma? Get tracking. More

And Finally... Device maker Medtronic ($MDT) said it had identified genetic abnormalities associated with sudden cardiac death. Report

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.